Compare Eli Lilly And Co (LLY) vs Prudential PLC (PUK) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Prudential PLC (PUK) trades at $28.275, showing minimal daily movement with a slight 0.05% decline. The stock presents strong fundamentals with a P/E of 9.21 and robust profitability metrics including 21.15% ROE and 14.52% net income margin. Recent earnings have exceeded expectations, with Q4 2025 EPS beating estimates by 46%. Technical indicators show a bullish overall signal despite mixed moving average signals, while analyst consensus leans positive with 50% buy ratings.

PUK offers attractive value with reasonable valuation multiples and consistent earnings growth, though faces headwinds from regulatory challenges in key markets like Japan and China. The company's strategic expansion in India through the Bharti Life acquisition and strong cash flow generation support long-term growth prospects, but investors should monitor regulatory developments in Asian markets.